ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110
The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial in children and adults with Leber’s congenital amaurosis 10. Foundation Fighting Blindness CEO Benjamin Yerxa, PhD. commented on ProQR’s lead program. Read what FFB's CEO had to say in Morningstar here.